How does Ann Arbor clean PFAS from its drinking water? City officials explain.
PFAS, or "forever chemicals," were first detected in Ann Arbor's drinking water in 2014. Two years later, the city performed a follow-up investigation and detected PFAS in the Huron River.
The river supplies the city with 85% of its drinking water.
"We traced it up to upstream manufacturing facilities and wastewater treatment plant discharges," said Ann Arbor Water Treatment Services manager Molly Maciejewski. "So, it was really industrial discharges that caused it, but we also know that there could be other sources of PFAS in the Huron River."
PFAS are highly stable, man-made chemicals used in many items. They're typically used to repel water, oil and grease from surfaces. PFAS spread easily and do not biodegrade naturally, making cleanup a challenge.
"Michigan was one of the first in the country to actually sample all of the drinking water supplies," said Abigail Hendershott, the executive director of the Michigan PFAS Action Response Team.
Hendershott said PFAS are all around us. They're found in clothing, furniture, cleaning products, outdoor gear, cosmetics and more.
"Most everybody in the country is going to have some concentrations of PFAS already in our blood because of the widespread use of PFAS in our everyday society," she said.
After extensive testing, officials at the Ann Arbor Water Treatment found an effective solution.
"We use granular-activated carbon filtration," said drinking water quality manager Becky Lahr. "So, you can see here the media inside the filter. The water travels from the top down through the filter, and the PFAS gets stuck within the media."
Lahr told CBS News Detroit the method filters out PFAS to below detectable levels in the drinking water.
"We are constantly monitoring the water quality before and after this process to make sure it's working right," Lahr said.
"Ann Arbor has been very aggressive in their actions, and we, of course, applaud them for that because they're being very proactive in protecting their residents," said Hendershott. "We want to make sure that the residents who are drinking this water are protected long term, that we're not just protecting for one or two chemicals, but we're protecting for the whole suite of PFAS chemicals."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 hours ago
- Yahoo
TEAMSTERS NURSES AT COREWELL TO RALLY AGAINST EMPLOYERS' ATTACKS
Nurses to Rally Outside Detroit Ahead of Contract Negotiations DETROIT, June 21, 2025 /PRNewswire/ -- Nurses at Corewell Health East, represented by Teamsters Local 2024, will rally on Saturday, June 21, to demand that their employer end its attacks on unionized workers. In November 2024, Corewell nurses beat back an aggressive $1.7 million union-busting campaign by organizing three-to-one to join the Teamsters. In the months since, corporate management at Corewell Health East has attacked nurses by withholding several economic opportunities that were given to nonunion employees, including refusing wage increases, withholding bonuses, and denying 403(b) matches. The rally comes three days before Teamsters are scheduled to begin negotiations with Corewell Health East for the first collective bargaining agreement for nearly 10,000 nurses. WHO: Corewell TeamstersFred Zuckerman, Teamsters General Secretary-TreasurerMike Smith, Trustee of Teamsters Local 2024Kevin Moore, President of Teamsters Joint Council 43 WHEN: Saturday, June 2110-11:30 a.m. WHERE: Corewell Health Southfield Center26901 Beaumont BlvdSouthfield, MI 48033Livestream will be available here. Media Contact: Lena Melentijevic, (347) 208-2279LMelentijevic@ On-site Contact: Kate Yeager, (484) 844-7239 View original content to download multimedia: SOURCE International Brotherhood of Teamsters Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Yahoo
Northern lights may be visible in these 9 US States tonight
When you buy through links on our articles, Future and its syndication partners may earn a commission. Unsettled geomagnetic activity could bring northern lights to parts of the U.S. tonight (June 19–20). A coronal mass ejection (CME) released during a relatively small C5.5 solar flare on June 17 may deliver a glancing blow to Earth sometime tonight. This, combined with fast solar wind streaming from a large Earth-facing coronal hole, could fuel geomagnetic storm conditions overnight, according to NOAA's Space Weather Prediction Center (SWPC). Space weather forecasters at SWPC predict a chance of minor G1 geomagnetic storm conditions (Kp 5) between 2 a.m. and 5 a.m. EDT (0600–0900 GMT) on June 20. (Kp is a measurement of geomagnetic activity, with an index that ranges from 0 to 9; higher Kp indicates stronger auroral activity.) You can keep up with the latest forecasts and geomagnetic storm warnings with our aurora forecast live blog. In the U.S., Alaska has the highest chance of seeing the northern lights tonight. If predicted G1 storms are reached, auroras could be visible down to Michigan and Maine, and perhaps even further according to NOAA. Below we have listed 9 states that appear either fully or in part above the possible view line for auroras tonight, according to NOAA's Space Weather Prediction Center. They are ordered most likely to least likely based on their proximity to the center of the auroral oval and how much of each state is within or near the view like Connecticut, Rhode Island, Nebraska, Iowa and Illinois are very close to the possible view line but would require stronger geomagnetic activity than forecast for visibility. That being said, geomagnetic storms have surprised us in the past, whereby forecasted G1 conditions jump to G2 or even G3. So it's worth keeping your eyes on the skies and those aurora alerts switched on. Remember, auroras can be fickle. Sometimes they can appear much farther south than predicted, and other times they barely show up at all. There are many conditions that have to align for the perfect show. It is possible that many more states could witness auroras tonight, or perhaps far fewer will. Alaska Montana North Dakota Minnesota Wisconsin Michigan (especially the Upper Peninsula) Maine Vermont New Hampshire If you live in one of the 9 states forecasted to have a chance of seeing the northern lights tonight, head to a north-facing vantage point as far away from light pollution as possible! The best time to look for auroras will be about 1 a.m. local time, as our window of darkness for observing the northern lights shrinks during summer months. Use your mobile phone to scan the skies, as the camera is great at picking up faint auroras before your eyes spot them. This can help you pinpoint where in the sky you should be focusing your attention. But remember to keep an eye out elsewhere too as auroras can pop up in front, behind or even above you! Happy aurora hunting. If you want to make sure you're all clued up on when to look for auroras, download a space weather app that provides forecasts based on your location. One option I use is "My Aurora Forecast & Alerts," available for both iOS and Android. However, any similar app should work well. I also use the "Space Weather Live" app, which is available on iOS and Android, to get a deeper understanding of whether the current space weather conditions are favorable for aurora sightings.
Yahoo
a day ago
- Yahoo
Cirius Therapeutics Announces Positive Data for MPC Inhibitor 0602K Alone and in Combination with Tirzepatide
MPC-inhibitor 0602K shows significant preservation of lean mass & increased muscle function combined with tirzepatide in pre-clinical DIO models 0602K shows profound beneficial transformation of adipose tissue in multiple ways & novel potential synergy with tirzepatide Both 0602K+tirzepatide and tirzepatide alone produced very similar rapid and substantial weight loss Pilot clinical study also shows 0602K by itself drives dramatic beneficial changes in muscle composition and metabolic function in patients with obesity & T2D Mitochondrial reprogramming with 0602K may add to benefits of GLP-1 weight loss with synergies in muscle & adipose tissues Data to be presented Sunday at ADA Scientific Sessions GRAND RAPIDS, Mich., June 20, 2025 /PRNewswire/ -- Cirius Therapeutics, Inc., a developer of innovative therapies for patients suffering from diseases caused by insulin resistance, including obesity/overweight and type 2 diabetes (T2D), today announced positive results from the first preclinical diet-induced obesity (DIO) studies demonstrating the potential benefits of combining 0602K and tirzepatide for patients with obesity / overweight, as well as from a pilot clinical study. Detailed data is being presented as a late-breaking poster at the American Diabetes Association's (ADA) 85th Scientific Sessions as well as a short oral presentation available online as part of the conference. "We have been advocating for the potential benefits of combining an insulin sensitizer with the latest incretin therapies, especially to more fully resolving the underlying metabolic dysfunctions in obesity, type 2 diabetes and other cardio-renal-metabolic diseases," said Dr. Ralph DeFronzo, MD, co-author and Professor of Medicine at the University of Texas Health Science Center at San Antonio. Dr. DeFronzo continued, "First generation insulin sensitizer pioglitazone has given us strong hints of the possibilities. Now, this very exciting preclinical data combining next generation insulin sensitizer 0602K with a state-of-the-art GLP-1/GIP receptor agonist, tirzepatide, further supports the enormous potential. The pilot clinical data further suggests 0602K has similar effects on body composition and metabolism in patients with obesity, and that combining the highly complementary mechanisms of 0602K and tirzepatide should drive benefits for patients beyond those already gained via weight loss." Collaborators at the Dasman Diabetes Institute in Kuwait and St. Louis University conducted parallel, independent DIO studies producing highly consistent results: Both 0602K+tirzepatide and tirzepatide alone produced very similar rapid and substantial weight loss through as long as 6 weeks treatment. 0602K + tirzepatide reduced the loss of lean mass and muscle typically seen with tirzepatide alone. Even more significantly, adding 0602K to tirzepatide increased both muscle strength and metabolic (mitochondrial) function by +50% each vs. tirzepatide alone. Adding 0602K to tirzepatide restored muscle strength/exercise capacity nearly to that of lean controls and increased mitochondrial abundance (number of mitochondria per muscle cell) by 50% over both lean controls and tirzepatide alone. 0602K + tirzepatide produced multi-faceted remodeling of adipose (fat) tissue, including reduced visceral-to-subcutaneous adipose tissue ratio (VAT:SAT), increased brown adipose tissue, and a synergistic transformation in subcutaneous adipose tissue (SAT) phenotype transformation. In SAT, 0602K and tirzepatide each produced marked decreases in adipocyte (fat cell) size, with the combination decreasing adipocyte size dramatically more than either alone. Smaller adipocytes are believed to be associated with several metabolic benefits, including an increase in numbers of "beige" adipocytes. Beige adipocytes actively consume stored fats and characteristically express uncoupling protein 1 (UCP-1), which aids in burning those fat calories. While both 0602K and tirzepatide increased UCP-1 protein in SAT by 2-3-fold over untreated high fat diet controls, the combination increased UCP1 ~7-fold with ~15% of cells UCP-1-positive. Separately, collaborators at the University of Texas Health Science Center at San Antonio conducted a small (n=3) pilot mechanistic clinical study of 0602K effects on muscle composition and metabolic function. In patients with obesity & T2D. assessed at baseline and after taking 250mg 0602K daily for 3 months: 0602K decreased intramyocellular lipid (fat inside muscle cells) by ~50% Increased muscle metabolic function (insulin-mediated glucose disposal) by ~50% Reduced HbA1c from an average of 8.33% at baseline to 6.97%. "These results support that targeting MPC with 0602K reprograms mitochondrial metabolism, not only reversing insulin resistance but also driving broad multi-organ benefits. Particularly important is 0602K synergy with GLP-1 receptor agonists we're describing here," remarked Dr. Jerry Colca, PhD, Cirius Chief Scientific Officer. Dr. Colca added, "0602K has previously been shown effective for T2D and MASH in Phase 2 clinical studies and without the side effect concerns that hung over earlier insulin sensitizers. These results highlight the need to explore the benefits of this combination particularly in patients with obesity / overweight." Cirius and several of the academic collaborators involved in the study will be available at the ADA poster (1982-LB) from 12:30-1:30 PM CDT this Sunday, June 22. Presentation Details: Title: 1982-LB - MPC-Directed Insulin Sensitizer MSDC-0602K Combines with Tirzepatide to Maintain Muscle Mass/Function and Restructure Adipose Tissue [Board No. 1982] Authors: M. Abu-Farha, J. Abubaker, F. Almulla – Dasman Diabetes Institute M. Abdul-Ghani, L. Norton, R.A. DeFronzo – University of Texas Health Sciences Center at San AntonioJ.R. Colca – Cirius TherapeuticsK.S. McCommis – St. Louis University Date & Time: Sunday, June 22, at 12:30 AM CT (poster will be up throughout meeting) Location: Poster Hall (Hall F1) About CiriusCirius is a clinical-stage pharmaceutical company focusing on mitochondrial pyruvate carrier (MPC), addressing the metabolic dysfunction that causes insulin resistance and the organ pathologies associated with type 2 diabetes (T2D) and obesity/overweight. Its lead product candidate, 0602K (azemiglitazone potassium), is a potential best-in-class novel small molecule being developed as a once-daily oral therapy designed to selectively inhibit the mitochondrial target MPC, which plays a central role in selecting mitochondrial energy substrates. MPC inhibition reprograms mitochondrial metabolism, reducing insulin resistance in cells and driving metabolic benefits in organs throughout the body. This markedly improves glycemic control in T2D, body composition in obesity, liver function and fibrosis in metabolic dysfunction-associated steatohepatitis (MASH), and outcomes in cardiometabolic disorders. About 0602K0602K has completed 7 US clinical trials including a 52-week placebo-controlled Phase 2b study in 392 subjects with MASH with and without T2D, and a 28-day placebo-controlled Phase 2a study in 129 subjects with T2D. In those clinical studies it markedly lowered HbA1c and insulin levels, and reduced liver injury and MASH – including on top of existing GLP-1 therapy. A pilot clinical study showed 0602K markedly both reduces fat in muscle and increases muscle metabolic function in patients with obesity & T2D. Preclinical studies also demonstrate increased lean muscle mass, strength and metabolic function, together with metabolically beneficial shifts in adipose tissue phenotype ("bad fat" to "good fat"), both alone and on top of GLP-1 and GLP-1/GIP agonists. In combination with GLP-1/GIP dual agonist tirzepatide, the transformation of subcutaneous adipose tissue includes dramatic reduction in adipocyte size and synergistic increase in "beiging." Selectively targeting MPC – while avoiding PPAR-γ activation – 0602K harnesses the real-world proven efficacy of 1st generation insulin sensitizers, such as pioglitazone, but without their side effect concerns. Directly correcting a major underlying pathophysiology of chronic metabolic disease, 0602K has the potential to become a cornerstone of therapy. Coupling this potent pharmacology with that of the GLP-1s could particularly benefit patients with T2D, obesity/overweight and other cardiometabolic diseases. View original content to download multimedia: SOURCE Cirius Therapeutics
